XML 43 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Business Segment Information (Tables)
9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Summary of Operating Segment and Asset Information

The following table summarizes operating segment information for the three and nine months ended September 30, 2021 and 2020, and asset information as of September 30, 2021 and December 31, 2020:

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Net revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Diagnostics

 

$

23,511

 

 

$

16,314

 

 

$

57,368

 

 

$

44,533

 

Molecular Solutions

 

 

30,406

 

 

 

31,697

 

 

 

112,738

 

 

 

64,333

 

Total

 

$

53,917

 

 

$

48,011

 

 

$

170,106

 

 

$

108,866

 

Operating income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

Diagnostics

 

$

(18,638

)

 

$

(9,951

)

 

$

(42,755

)

 

$

(31,116

)

Molecular Solutions

 

 

5,625

 

 

 

14,336

 

 

 

41,962

 

 

 

18,054

 

Total

 

$

(13,013

)

 

$

4,385

 

 

$

(793

)

 

$

(13,062

)

Depreciation and amortization:

 

 

 

 

 

 

 

 

 

 

 

 

Diagnostics

 

$

1,136

 

 

$

934

 

 

$

2,965

 

 

$

2,448

 

Molecular Solutions

 

 

2,199

 

 

 

1,517

 

 

 

5,514

 

 

 

4,432

 

Total

 

$

3,335

 

 

$

2,451

 

 

$

8,479

 

 

$

6,880

 

Capital expenditures:

 

 

 

 

 

 

 

 

 

 

 

 

Diagnostics

 

$

3,647

 

 

$

2,186

 

 

$

19,797

 

 

$

5,634

 

Molecular Solutions

 

 

932

 

 

 

3,011

 

 

 

7,711

 

 

 

5,600

 

Total

 

$

4,579

 

 

$

5,197

 

 

$

27,508

 

 

$

11,234

 

 

 

 

 

September 30, 2021

 

 

December 31, 2020

 

Total assets:

 

 

 

 

 

 

Diagnostics

 

$

206,668

 

 

$

242,613

 

Molecular Solutions

 

 

249,089

 

 

 

211,859

 

Total

 

$

455,757

 

 

$

454,472